News About: R&D
Drug makers cancel licenses of 43,109 medicines voluntarily for 5 years
Pharmaceutical companies have voluntarily cancelled a total of 43,109 drugs since 2003, according to the Korea Food and Drug Administration.
These voluntarily-cancelled items are chiefly related to little marketabi...
Bioequivalence testing to be compulsory on combined generic drugs
Local drug makers will be obliged to conduct bioequivalence testing of combined generic products, according to market sources.
The Korea Food and Drug Administration said it plans to introduce bioequivalence testin...
Neobio, Korea University sign MOU on development of new natural products
Neobio, a leader in the field of cutting-edge biotechnology, said on August 25 that it signed a memorandum of understanding with the Korea University’s medical college to conduct joint research for the development of ...
10 leading pharmaceuticals firms conducing 90 projects for drug development
Korea’s 10 leading pharmaceutical companies have conducted a total of 90 projects aiming to develop new drugs, according to the report compiled by Samjong-KPMG Group.
Dong-A Pharm came in first with 20 projects, fo...
Clinical results of clevudine to be published in international liver meeting
Bukwang Pharm says the comparative clinical results of clevudine over Hepsera will be published in the 13th International Symposium to be organized by the American Association for the Study of Liver Diseases (AASLD).
...
Medifocus launches symptomatic treatment of eczemaMedifocus says it has launched Nanoclair, a nonsteroidal cream to soothe eczema through its importation from the U.K. based Sinclair Pharmaceuticals Ltd.
According to the com...
|
Huons launches piogligtazone 15 mgHuons says it has launched piogligtazone 15 mg, an oral antidiabetic agent that acts primarily by decreasing insulin resistance.
Piogligtazone is used in the management of ty...
|
GCC markets pioglitazone tabletsGreen Cross Corp. has launched Glulis (pioglitazone) tablets with an aim to strengthen its diabetic sector in addition to glimepiride and metformin.
Pioglitazone is a prescri...
|
Dream Pharma to introduce new asthma inhaler
Dream Pharma Corp. says it has signed an exclusive agreement with Belgium based Laboratoires SMB to locally distribute 'Flutaxa', a dry inhaler for treatment of asthma in 2010.
Flutaxa inhaler, containing fluticaso...
Anterogen files stem-cell related patent
Anterogen Co., an affiliated company of Bukwang Pharm, says it has filed a patent application for adipose-derived stem cells to treat bowel or fecal incontinence.
The patent is characterized by a cellular compositi...
